|
News For NKTR;SLXP From The Last 14 Days Check below for free stories on NKTR;SLXP the last two weeks. |
|
|
| June 19, 2013 |
| 10:11 EDT |  | NKTR | Nektar to host conference call
 Subscribe for More Information |
|
| June 18, 2013 |
| 07:52 EDT |  | SLXP | Salix price target raised to $76 from $69 at Brean Capital
Brean Capital raised its price target on Salix to reflect the addition of chronic OIC to its Relistor model. Shares are Buy rated. |
|
| June 13, 2013 |
| 06:58 EDT | | SLXP | Salix price target raised to $79 from $63 at Piper Jaffray
Subscribe for More Information |
|
| June 12, 2013 |
| 10:14 EDT |  | SLXP | On the Fly: Upgrade Summary
Subscribe for More Information |
|
| 08:39 EDT | | SLXP | Salix upgraded to Buy from Neutral at Buckingham
Subscribe for More Information |
|
| June 11, 2013 |
| 11:38 EDT | | SLXP | Salix news for Relistor an unexpected positive, says Cantor
Cantor views the FDA planning to convene a panel to discuss the status of Salix's Relistor for opioid induced constipation as an unexpected positive and reiterates a Buy rating on Salix shares. The firm says the panel, likely to be held in the next 3-4 months, could be another meaningful catalyst for the stock. |
|
| 11:20 EDT | | SLXP | Salix shares pricing in Relistor value, says Leerink
Leerink attributes today's move higher in shares of Salix Pharmaceuticals to the FDA reviewing its Relistor drug for opioid induced constipation as most investors had removed Relistor for OIC from the stock's valuation. However, Leerink cautions against paying more than $3 per share on this news due to risk of the FDA requiring more studies pre-approval and the drug's questionable benefit versus generic laxatives. The firm keeps a Market Perform rating on shares of Salix. |
|
| 09:04 EDT |  | SLXP | Salix, Progenics say FDA committee to review Relistor sNDA
Subscribe for More Information |
|
| 08:23 EDT | | SLXP | Salix price target raised to $69 from $57 at Brean Capital
Subscribe for More Information |
|
|
|
|
|
